Media headlines about OvaScience (NASDAQ:OVAS) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a news impact score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.3001454786299 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
Several brokerages have recently weighed in on OVAS. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of OvaScience in a report on Monday, November 6th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Wednesday, October 4th.
Shares of OvaScience (NASDAQ:OVAS) opened at $1.18 on Friday. OvaScience has a one year low of $1.08 and a one year high of $2.05. The company has a market capitalization of $42.13, a price-to-earnings ratio of -0.64 and a beta of 3.73.
ILLEGAL ACTIVITY WARNING: “OvaScience (NASDAQ:OVAS) Receiving Somewhat Favorable News Coverage, Accern Reports” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/ovascience-ovas-given-daily-news-impact-score-of-0-12.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.